

27 March 2026

POLYCYSTIC KIDNEY DISEASE – PRESENTATION AT WORLD CONGRESS OF NEPHROLOGY

- **PYC is progressing a drug candidate (known as PYC-003) that addresses the underlying cause of Polycystic Kidney Disease (PKD) through clinical trials**
- **The Company today announces that it will present a poster on progress in the PYC-003 program at the World Congress of Nephrology (WCN) from 28 to 31 March in Yokohama, Japan**
- **A copy of the poster presentation is attached to this announcement**
- **Comprehensive safety and efficacy data from the ongoing Phase 1a Single Ascending Dose (SAD) study¹ in both healthy volunteers and PKD patients is expected to be presented in H2 CY26²**
- **PYC expects to initiate the Phase 1b Multiple Ascending Dose (MAD) study of PYC-003 in PKD patients in Q2 CY26 with safety and efficacy data from the MAD study expected to be presented in CY27³**

PERTH, Australia and SAN FRANCISCO, California – 27 March 2026

PYC Therapeutics Limited (ASX:PYC) (PYC or the Company) is a precision medicine Company dedicated to changing the lives of patients with genetic diseases who have no treatment options available.

The Company currently has three clinical-stage drug development programs including a drug candidate (known as PYC-003) that addresses the underlying cause of Polycystic Kidney Disease (PKD). PYC today announces that it will present a poster update on progress in the PYC-003 drug development program at the World Congress of Nephrology (WCN) from 28 to 31 March in Yokohama, Japan.

A copy of the poster presentation is attached to this announcement.

¹ See ASX announcements of 10 February 2025, 10 April 2025, 26 May 2025, 7 July 2025, 8 August 2025, 24 November 2025, 19 December 2025, 27 February 2026, 23 March 2026

² Subject to the risks and uncertainties outlined in the Company's ASX disclosures of 2 February 2026

³ Subject to the risks and uncertainties outlined in the Company's ASX disclosures of 2 February 2026

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – the indications with the highest likelihood of success in clinical development⁴.

For more information, visit pyctx.com, or follow us on [LinkedIn](#) and [X](#).

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations, and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations, and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited

CONTACT US

Investor relations and media contact
investor@pyctx.com



⁴ Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank
<https://doi.org/10.1101/2020.11.02.2022232>

